Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/102654
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSmith, Danielle E.-
dc.contributor.authorBorg Xuereb, Christian-
dc.contributor.authorPattison, Helen M-
dc.contributor.authorLip, Gregory YH-
dc.contributor.authorLane, Deirdre A.-
dc.date.accessioned2022-10-14T04:53:35Z-
dc.date.available2022-10-14T04:53:35Z-
dc.date.issued2010-
dc.identifier.citationSmith, D. E., Borg Xuereb, C., Pattison, H. M., Lip, G. Y., & Lane, D. A. (2010). TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT). BMC Cardiovascular Disorders, 10: 21.en_GB
dc.identifier.urihttps://www.um.edu.mt/library/oar/handle/123456789/102654-
dc.description.abstractBackground: Atrial fibrillation (AF) patients with a high risk of stroke are recommended anticoagulation with warfarin. However, the benefit of warfarin is dependent upon time spent within the target therapeutic range (TTR) of their international normalised ratio (INR) (2.0 to 3.0). AF patients possess limited knowledge of their disease and warfarin treatment and this can impact on INR control. Education can improve patients' understanding of warfarin therapy and factors which affect INR control. Methods/Design: Randomised controlled trial of an intensive educational intervention will consist of group sessions (between 2-8 patients) containing standardised information about the risks and benefits associated with OAC therapy, lifestyle interactions and the importance of monitoring and control of their International Normalised Ratio (INR). Information will be presented within an 'expert-patient' focussed DVD, revised educational booklet and patient worksheets. 200 warfarin-naïve patients who are eligible for warfarin will be randomised to either the intervention or usual care groups. All patients must have ECG-documented AF and be eligible for warfarin (according to the NICE AF guidelines). Exclusion criteria include: aged < 18 years old, contraindication(s) to warfarin, history of warfarin USE, valvular heart disease, cognitive impairment, are unable to speak/read English and disease likely to cause death within 12 months. Primary endpoint is time spent in TTR. Secondary endpoints include measures of quality of life (AF-QoL-18), anxiety and depression (HADS), knowledge of AF and anticoagulation, beliefs about medication (BMQ) and illness representations (IPQ-R). Clinical outcomes, including bleeding, stroke and interruption to anticoagulation will be recorded. All outcome measures will be assessed at baseline and 1, 2, 6 and 12 months post-intervention. Discussion: More data is needed on the clinical benefit of educational intervention with AF patients receiving warfarin.en_GB
dc.language.isoenen_GB
dc.publisherBioMed Central Ltd.en_GB
dc.rightsinfo:eu-repo/semantics/openAccessen_GB
dc.subjectAtrial fibrillation -- Treatmenten_GB
dc.subjectHeart -- Diseases -- Patientsen_GB
dc.subjectAnticoagulants (Medicine) -- Therapeutic useen_GB
dc.subjectWarfarinen_GB
dc.subjectCerebrovascular disease -- Preventionen_GB
dc.titleTrial of an educational intervention on patients' knowledge of atrial fibrillation and anticoagulant therapy, INR control, and outcome of treatment with warfarin (TREAT)en_GB
dc.typearticleen_GB
dc.rights.holderThe copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder.en_GB
dc.description.reviewedpeer-revieweden_GB
dc.identifier.doi10.1186/1471-2261-10-21-
Appears in Collections:Scholarly Works - FacSoWGer



Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.